K
Kaoru Uchimaru
Researcher at University of Tokyo
Publications - 148
Citations - 3721
Kaoru Uchimaru is an academic researcher from University of Tokyo. The author has contributed to research in topics: Leukemia & Transplantation. The author has an hindex of 26, co-authored 130 publications receiving 3043 citations. Previous affiliations of Kaoru Uchimaru include RMIT University & Waseda University.
Papers
More filters
Journal ArticleDOI
Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies.
Satoshi Takahashi,Tohru Iseki,Tohru Iseki,Jun Ooi,Jun Ooi,Akira Tomonari,Akira Tomonari,Kashiya Takasugi,Kashiya Takasugi,Yoko Shimohakamada,Yoko Shimohakamada,Toshiki Yamada,Toshiki Yamada,Kaoru Uchimaru,Kaoru Uchimaru,Arinobu Tojo,Arinobu Tojo,Naoki Shirafuji,Naoki Shirafuji,Hideki Kodo,Hideki Kodo,Kenzaburo Tani,Kenzaburo Tani,Tsuneo A. Takahashi,Tsuneo A. Takahashi,Takuhiro Yamaguchi,Takuhiro Yamaguchi,Shigetaka Asano,Shigetaka Asano +28 more
TL;DR: Data suggest that CBT could be safely and effectively used for adult patients with hematologic malignancies and showed better TRM and DFS results compared with BMT, despite the higher human leukocyte antigen mismatching rate and lower number of infused cells.
Journal ArticleDOI
Polycomb-Mediated Loss of miR-31 Activates NIK-Dependent NF-κB Pathway in Adult T Cell Leukemia and Other Cancers
Makoto Yamagishi,Kazumi Nakano,Ariko Miyake,Tadanori Yamochi,Yayoi Kagami,Akihisa Tsutsumi,Yuka Matsuda,Aiko Sato-Otsubo,Satsuki Muto,Atae Utsunomiya,Kazunari Yamaguchi,Kaoru Uchimaru,Seishi Ogawa,Toshiki Watanabe +13 more
TL;DR: A pathway involving Polycomb-mediated miRNA silencing and NF-κB activation is reported and a perspective involving the epigenetic program, inflammatory responses, and oncogenic signaling is provided.
Journal ArticleDOI
Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan.
Masako Iwanaga,Masako Iwanaga,Toshiki Watanabe,Atae Utsunomiya,Akihiko Okayama,Kaoru Uchimaru,Ki-Ryang Koh,Masao Ogata,Hiroshi Kikuchi,Yasuko Sagara,Kimiharu Uozumi,Manabu Mochizuki,Kunihiro Tsukasaki,Yoshio Saburi,Masaomi Yamamura,Junji Tanaka,Yukiyoshi Moriuchi,Shigeo Hino,Shimeru Kamihira,Kazunari Yamaguchi +19 more
TL;DR: Multivariate Cox analyses indicated that not only a higher proviral load, advanced age, family history of ATL, and first opportunity for HTLV-1 testing during treatment for other diseases were independent risk factors for progression of ATL.
Journal ArticleDOI
Targeting EZH2 in cancer therapy.
Makoto Yamagishi,Kaoru Uchimaru +1 more
TL;DR: The present review introduces recent outstanding progress pertaining to Enhancer of zeste homolog 2 (EZH2), especially regarding its mode of action as a master regulator of chromatin, and provides molecular-based evidence for targeting EZh2 in cancer therapy.
Journal ArticleDOI
Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report
Lucy Cook,Shigeo Fuji,Olivier Hermine,Ali Bazarbachi,Juan Carlos Ramos,Lee Ratner,Steve Horwitz,Paul Fields,Alina Tanase,Horia Bumbea,Kate Cwynarski,Graham P. Taylor,Thomas A. Waldmann,Achiléa L. Bittencourt,Ambroise Marçais,Felipe Suarez,David Sibon,Adrienne A. Phillips,Matthew A. Lunning,Reza Farid,Yoshitaka Imaizumi,Ilseung Choi,Takashi Ishida,Kenji Ishitsuka,Takuya Fukushima,Kaoru Uchimaru,Akifumi Takaori-Kondo,Yoshiki Tokura,Atae Utsunomiya,Masao Matsuoka,Kunihiro Tsukasaki,Toshiki Watanabe +31 more
TL;DR: This expert consensus highlights the need for additional clinical trials to develop novel standard therapies for the treatment of ATL and recommends up-front allogeneic hematopoietic stem-cell transplantation and novel agents.